Holen Sie sich die Stockscreener-App
432.52
0.60%
2.59
Handel nachbörslich:
432.52
Schlusskurs vom Vortag:
$429.93
Offen:
$428.43
24-Stunden-Volumen:
2.09M
Relative Volume:
2.04
Marktkapitalisierung:
$56.69B
Einnahmen:
$2.46B
Nettoeinkommen (Verlust:
$-319.09M
KGV:
-175.11
EPS:
-2.47
Netto-Cashflow:
$-52.09M
1W Leistung:
+1.02%
1M Leistung:
+37.33%
6M Leistung:
+63.28%
1J Leistung:
+61.61%
1-Tages-Spanne:
$421.81
$438.23
1-Wochen-Bereich:
$421.81
$445.20
52-Wochen-Spanne:
$205.87
$445.20
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Promising Biotech Stocks Worth WatchingAugust 12th - MarketBeat
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Valuation Update]Low Risk Entry Point Tips - sisaissue.com
Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation - AInvest
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - MSN
Alnylam at Canaccord Genuity: Strategic Growth and Innovation - Investing.com
Alnylam Pharmaceuticals at Canaccord Genuity's 45th Annual Growth Conference - AInvest
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - BioSpace
Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock - Yahoo Finance
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Up 9.2% After Upward Q2 Revenue Guidance Revision and Higher Analyst Forecasts—Has the Bull Case Changed? - simplywall.st
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN Brasil
Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity - AInvest
Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating - TipRanks
Does Alnylam’s (ALNY) Upbeat Revenue Forecast Signal Shifting Momentum in Its Long-Term Growth Story? - simplywall.st
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop - AInvest
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD By Investing.com - Investing.com Canada
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
Alnylam Slips 0.15% Despite $760M Volume Ranking 137th in U.S. Equities as Mixed Pipeline Data Weigh on Momentum - AInvest
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire
Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance
U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada
Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada
Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance
Alnylam Pharmaceuticals Surges 3.79% Intraday – What’s Fueling This Sudden Rally? - AInvest
Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says - MarketScreener
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st
What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsTremendous growth potential - Jammu Links News
When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - Jammu Links News
How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - Jammu Links News
What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - Jammu Links News
Does Alnylam Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on momentum-driven investment opportunities - Jammu Links News
How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyConsistently superior profits - Jammu Links News
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyUnlock powerful stock screening tools today - Jammu Links News
How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketCapitalize on strong market momentum - Jammu Links News
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastMaximize gains with strategic stock entries - Jammu Links News
What are the technical indicators suggesting about Alnylam Pharmaceuticals Inc.Discover the fastest growing stocks today - Jammu Links News
Published on: 2025-08-03 13:52:50 - Jammu Links News
What catalysts could drive Alnylam Pharmaceuticals Inc. stock higher in 2025Exceptional risk-adjusted gains - Jammu Links News
Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access - AInvest
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - MSN
Is it the right time to buy Alnylam Pharmaceuticals Inc. stockBreakout Stocks Signals Backed By Experts - jammulinksnews.com
Alnylam’s Q2 2025 Earnings Call Highlights Robust Growth - TipRanks
BMO Capital Reaffirms Buy Rating on Alnylam Pharma with $450 Price Target - AInvest
Alnylam Pharmaceuticals Lifts Revenue Outlook After Earnings Beat - Finimize
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Option Exercise |
118.73 |
19,297 |
2,291,057 |
68,245 |
| Greenstreet Yvonne | Chief Executive Officer |
May 30 '25 |
Sale |
304.39 |
31,640 |
9,630,902 |
48,948 |
| Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Sale |
306.00 |
19,297 |
5,904,882 |
48,948 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):